ABSTRACT

Stratified medicine is recognized as a key global priority for healthcare providers, patients, and pharmaceutical and diagnostic industries. Achieving personalized care with provision of the “right treatment, for the right person, at the right time” should be an inevitable progression as we gain greater understanding of the etiology and pathophysiology of disease, but requires critical assessment of all aspects of care. Advances in understanding have enabled us to predict disease reliably at population levels, with existing and novel biomarkers now being evaluated for incorporation into composite models (1). Reproductive medicine has taken a notable lead in the use of prognostic models for stratification of individuals to different likelihoods of success, in the utilization of novel biomarkers for predicting ovarian response and assigning risk, and for developing novel therapeutic algorithms to allow streamlining of individuals to the appropriate intervention.